Andrew Slack Email & Phone Number

Beijing, CN

Reporting to Chief Business Officer, responsible for global business & sales management of Pharmaron's Radiolabeled Sciences (RLS), Advanced Bioanalytical Sciences (ABS) and Clinical Pharmacology (CPC) divisions in US, EU and Japan. Manage and integrate several BD teams across 3 continents covering radiosynthesis, in vitro and in vivo drug metabolism.

Beijing, CN

Reporting to the SVP, Strategic Partnerships, responsible for commercial integration of Pharmaron's clinical development services for Pharmaceuticals/Biopharmaceuticals including Accelerator Mass Spectrometry (AMS), Clinical Pharmacology (Phase I, IIa), Radiosynthesis/Radiolabeling (14C/3H), and, both non-clinical and clinical metabolism (ADME) including.

Germantown, MD, US

Xceleron was acquired by Pharmaron in January, 2017 and is a fully-owned subsidiary of Pharmaron. Xceleron is a highly specialized CRO that pioneered the biomedical applications of ultra-sensitive AMS (Accelerator Mass Spectrometry) technology. We employ AMS in a number of different ways as a valuable translational tool to bridge "bench to bed" more.

London, GB

• VP-level position (reported to EVP, Chemicals & Pharmaceuticals Division) responsible for providing overall strategic direction, developing and implementing sales and marketing plans to leverage global business.
• Led formation of cross-divisional Intertek medical team to expand a $20M business in the medical devices sector by combining several service areas into a single consolidated service offering
• Developed a strategic business plan to drive both organic growth of existing pharmaceutical businesses, and new growth via M&A to increase annual revenues from $50M to $500M in 5-years
• Developed brand for Intertek Pharmaceutical Services within the corporate brand strategy and re-designed the web-site, authoring entire content, that increased web-site traffic by 30% in 12-months
• Achieved a reputation as the internal ‘go-to’ expert for cross-referring analytical projects within Chemicals & Pharmaceuticals Division ($235M annual revenues with 1,600 staff)

• C-level position (reported to CEO) at the Holding Company and worked very closely with the CFO and Behrman Capital (private equity owners) to maximize shareholder value. Responsible for planning and directing marketing.
• Assisted with M&A and organic growth plans that increased group revenues from $107M to $140M over 2-years and ensured the Dutch operation achieved goals of $34.5M (2006) and $39M (2007)
• Assisted with gaining board approval for a $15M capital investment and business plan to generate additional annual revenues of $50M by 2009
• Exceeded sales and profit targets 2006-2007 and contributed to successful $500M sale and exit strategy for Behrman Capital that generated a ROI in WIL Research Holding Co. of 3.6x in 4-years
• Due diligence and business plans leading to successful acquisition of QS Pharma for $19M in 2006
• Established single representation in Japan through hiring a new Head Business Development in Tokyo and led technology transfer for a specialized service area from WIL (Ohio) to NOTOX (Netherlands)

Akron, Ohio, US

Reported to Managing Director, Springborn Smithers (65 staff), responsible for the strategy and business plan that led to the successful launch of new contract Analytics Company for Smithers called Synomics Pharma Services. Implemented a customer service program, marketing and promotional initiatives, pricing policies, and assisted with management of.

Wilmington, Massachusetts, US

• VP-level position (reported to President & CEO) and Member of Executive Committee that managed company with 1,200 staff. Responsible for preclinical sales, contracts, customer service, marketing and promotional plans.
• Appointed Chairman of Corporate R&D Committee with 8 Scientific Directors to manage and fund new initiatives to expand the services portfolio and fuel organic growth
• Introduced cost recovery processes that consistently yielded $12M+ per year in additional revenues
• Successfully re-branded company profile and value proposition twice following mergers
• Helped increase annual revenues at CTBR from $50M to $135M in 7-years leading to merger with Inveresk Research and a record sale to Charles River Labs valued at 23x EBITDA multiple in 2004
• Exceeded sales and profit targets every year from 1997 to 2004

Wilmington, Massachusetts, US

Huntingdon, Cambridgeshire, GB

Wilmington, Massachusetts, US